DANBURY's MINOXIDIL ANDA APPROVAL IS FIRST GENERIC version of Upjohn's antihypertensive agent Loniten. The patent for Loniten expired in July 1985. FDA approved the generic oral minoxidil in 2.5 mg and 10 mg tablets on March 3 and the company began shipping the product March 6. Introduced in 1979, Loniten sales increased dramatically in 1983 and 1984 due to recompounding of the drug for use as an antibaldness treatment. Analysts' estimates of Loniten annual sales are in the $30 mil. range with well over half coming from the unapproved baldness use. Upjohn's NDA for the topical antibaldness drug Rogaine is to be reviewed by FDA's Dermatologic Drugs Advisory Committee March 16. Last April FDA directed its regional compliance offices to issue regulatory letters to approximately 50 firms, primarily hair and scalp treatment centers, that were understood to be promoting reformulated minoxidil for hair growth. In August 1985 the agency requested Upjohn to change minoxidil labeling to specifically caution against recompounding for hair regeneration.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.
Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.
